Elpiscience Receives the US FDA’s IND Clearance of ES014 for the Treatment of Advanced Solid Tumors
Shots:
- The US FDA has cleared the IND application of ES014 (anti-CD39xTGF-β bispecific Ab) to initiate a P-I clinical study for the treatment of advanced solid tumors
- In preclinical studies, ES014 showed significant anti-tumor activity in a PD-1 resistant in vivo efficacy model
- ES014 was designed to target CD39-adenosine & TGF-β pathways while anti-CD39 activity can reverse TME immunosuppression by reducing suppressive adenosine & maintains high levels of immune-stimulatory extracellular ATP. The company has built a robust pipeline of cancer immunotherapies covering oncology targets & multiple technologies including the BiME Ab platform for solid tumors
Ref: Businesswire | Image: Elpiscience
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
